Latoxan Overview
- Year Founded
-
1982
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
Latoxan General Information
Description
Developer of venoms and toxins designed to sell to pharmaceutical companies, medical research laboratories and drug discovery units throughout the world. The company's venoms and toxins are produced under controlled conditions from animals, plant compounds and other similar pharmacological tools, enabling clients to develop medicinal products and drugs with natural compounds.
Contact Information
Website
www.latoxan.comCorporate Office
- ZA Les Auréats, 845 Avenue Pierre Brossolette
- 26800 Portes-lès-Valence
- France
Corporate Office
- ZA Les Auréats, 845 Avenue Pierre Brossolette
- 26800 Portes-lès-Valence
- France
Latoxan Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Secondary Transaction - Private | 01-Mar-2021 | Completed | Generating Revenue | |||
| 1. Later Stage VC | 01-Jun-2015 | Completed | Generating Revenue |
Latoxan Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Latoxan Patents
Latoxan Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3838286-A1 | Antimicrobial peptide from polistes gallicus venom and its analogs | Pending | 19-Dec-2019 | ||
| CA-2906241-A1 | Use of spider venoms for skin whitening/depigmenting and composition comprising spider venoms molecules or synthetic analogs | Inactive | 05-Sep-2012 | ||
| US-20150231061-A1 | Use of spider venoms for skin whitening/depigmenting and composition comprising spider venoms molecules or synthetic analogs | Active | 05-Sep-2012 | ||
| US-10064814-B2 | Use of spider venoms for skin whitening/depigmenting and composition comprising spider venoms molecules or synthetic analogs | Inactive | 05-Sep-2012 | ||
| FR-2994847-B1 | Use of spider venoms for bleaching or depigmentation of the skin and compositions including spider venom molecules or synthetic analogues thereof | Inactive | 05-Sep-2012 | A61K8/987 |
Latoxan Executive Team (1)
| Name | Title | Board Seat |
|---|---|---|
| Harold Pomyers | Chief Executive Officer & President |
Latoxan Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Latoxan Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| IRD Invest | Venture Capital | Minority |
Latoxan FAQs
-
When was Latoxan founded?
Latoxan was founded in 1982.
-
Who is the CEO of Latoxan?
Harold Pomyers is the CEO of Latoxan.
-
Where is Latoxan headquartered?
Latoxan is headquartered in Portes-lès-Valence, France.
-
What is the size of Latoxan?
Latoxan has 7 total employees.
-
What industry is Latoxan in?
Latoxan’s primary industry is Biotechnology.
-
Is Latoxan a private or public company?
Latoxan is a Private company.
-
What is Latoxan’s current revenue?
The current revenue for Latoxan is .
-
Who are Latoxan’s investors?
IRD Invest has invested in Latoxan.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
